What the MHRA has ordered

The Medicines and Healthcare products Regulatory Agency issued Device Safety Information DSI/2026/007 on 10 August 2026 after finding that six medical device lines had been supplied on the UK market without valid UKCA or CE conformity markings or supporting certification. Healthcare organisations must identify any affected products, stop using and supplying them immediately, quarantine remaining stock, use compliant alternatives and retain the devices pending further MHRA advice. The instruction applies to stock in clinical use, stores or any local supply function. It is not limited to unopened central inventory.1, 2

The six lines are VAKU-8 Blood Collection, Infusion and Scalp Vein Set from Hindustan Syringes and Medical Devices Ltd, Bipson Gauze Swab Sterile from Bipson Surgical Private Ltd, Technocut Scalpel from Niraj Industries Ltd, Romsons Alco Swabs from Romsons Group Private Ltd, Medi Grip Adhesive Bandage marked Antiseptic from Precision Coatings (P) Ltd, and Bone Marrow Biopsy Needle from Meditech Devices Pvt. Ltd. The MHRA alert includes product images because a name in a catalogue or stock system may not reproduce all wording shown on the packaging.1, 2

These products span blood collection and infusion, surgery, biopsy, wound care and skin preparation. That range means the search cannot be left to one specialty. Procurement, pathology, theatres, wards, outpatient services, community stores and any organisation that redistributes supplies may hold different items. The alert asks providers to ensure relevant staff receive the information and understand the required actions. A central email without a documented stock search would not establish whether all affected locations had been checked.1, 2

Distributors must cease supply, identify stock within their possession or control, inform customers who may have received it and maintain records of onward distribution. Any organisation that believes it has received, supplied or distributed an affected product should notify devices.compliance@mhra.gov.uk, quote DSI/2026/007 and provide onward distribution details where known. Traceability therefore runs in both directions. A service needs to establish where stock came from, where it was stored and whether any was transferred to another site or provider.1, 2

What the alert does not establish

The MHRA states that it has not identified a specific device defect, performance issue, quality issue or safety signal associated with these products. That limit is central to an accurate account. The action was triggered by the absence of legitimate conformity evidence required for supply, not by a reported pattern of breakage, contamination, treatment failure or patient injury. Describing the products as proven dangerous or defective would go beyond the regulator’s findings and could cause unnecessary concern for people who previously received care involving one of them.1, 2

The absence of an identified signal is not a declaration that the devices meet the required standards. The regulator says that without valid UKCA or CE certification it cannot obtain sufficient assurance about conformity assessment, quality management systems, safety, sterility and performance. Those are questions about the evidence supporting legal market access. A product may appear intact and work during an individual procedure while its manufacturing and certification record remains inadequate. Visual inspection alone cannot replace the missing regulatory assurance.1, 2

Quarantine is consequently a precautionary control while the affected stock remains available for investigation and further instruction. It is different from quietly disposing of items, sending them back without a record or allowing staff to use them until replacements arrive. Retention preserves product identity, packaging, batch information and the possibility of inspection. Services should keep quarantined stock physically or electronically segregated according to local procedures and restrict release. The MHRA, rather than an individual ward or supplier, should determine the next regulatory step.1, 2

The alert also says there is no advice for healthcare professionals to provide to patients specifically because of this Device Safety Information. That statement should not be rewritten as proof that exposure could never matter. If a person has symptoms, a clinical concern or a suspected device incident, the ordinary assessment and reporting routes still apply. The communication is aimed at stopping further use and securing stock. It does not call for a general patient recall or retrospective testing programme, and services should not invent one without clinical or regulatory evidence.1, 2

Why conformity evidence matters

The Medical Devices Regulations 2002 provide the legal framework for medical devices placed on the market in Great Britain, alongside arrangements that continue to recognise qualifying CE marked devices. The applicable route depends on the device, its classification, the market and transitional provisions. Some devices require assessment by an approved or notified body, while limited lower risk routes allow a manufacturer declaration. In each case the mark must rest on the correct procedure and documentation. A symbol printed on packaging is not valid merely because it resembles a UKCA or CE mark.3, 4

A declaration of conformity records the manufacturer’s responsibility for meeting the relevant requirements. Where third party assessment is required, valid certification from the appropriate body is part of the evidence. Technical documentation, quality systems, labelling and registration obligations support the claim. The MHRA guidance explains that a UKCA mark signifies conformity with the UK regulations and fitness for the stated intended purpose. It does not mean that every possible clinical outcome is guaranteed, and it does not remove the need for vigilance after a device enters use.3, 4

The regulatory route also differs between Great Britain and Northern Ireland. Great Britain comprises England, Wales and Scotland for these market rules, while Northern Ireland follows distinct arrangements involving EU device legislation and, in some circumstances, UKNI marking. The DSI is a UK communication and gives incident reporting routes for all four nations. Procurement teams should therefore verify the evidence appropriate to the place of supply rather than assume that one marking statement covers every UK destination.3, 4

Clinical staff are not expected to reconstruct a manufacturer’s technical file before using routine stock. Organisations and economic operators carry the primary purchasing, supply and regulatory checks. Staff still need a workable way to recognise an alert, match it to the product in front of them and escalate uncertainty. Packaging name, manufacturer, catalogue details, batch or lot and supplier record may all be needed. A local policy that says only to look for a mark can fail when the mark or certificate itself is the subject of the concern.3, 4

How services should control the stock

A reliable search starts with the exact product and manufacturer combinations in the DSI. Procurement systems can identify purchase orders and suppliers, but local cupboards, procedure packs and community bases may not be represented accurately in the main inventory. Services should assign responsibility for checking each relevant area and record completion, quantity found, batch information and current location. Staff should preserve packaging where possible because it may carry the identifiers needed to distinguish an affected line from a compliant alternative with a similar clinical purpose.1, 2, 4

Any match should be removed from availability without waiting for a report of harm. The quarantine area should prevent accidental selection, retain the product in its current condition and show the alert reference and date. Electronic stock records should also prevent replenishment or transfer. Where an item has been incorporated into a locally assembled pack, the whole pack may need to be held until the affected component can be identified and managed safely. Local device safety, procurement and infection prevention teams can coordinate that decision.1, 2, 4

Replacing stock requires more than choosing an item that looks similar. The alternative must be legally supplied, suitable for the intended procedure and compatible with connected equipment, local protocols and staff competence. A change in blood collection set, biopsy needle or skin preparation product can alter technique, sizing, connectors, sterility arrangements or allergy considerations. Clinical and procurement leads should confirm the substitute, communicate any differences and avoid creating a second risk through hurried substitution. If compliant supply is constrained, the issue should be escalated through service continuity arrangements.1, 2, 4

Records should distinguish stock found, stock quarantined, stock previously used and stock supplied onward. The DSI does not require a retrospective clinical review of every use, but traceability information may become important if the MHRA issues further advice. Services should not create unsupported patient lists from incomplete stock estimates. If records can link a specific device and procedure lawfully, they should be retained under existing governance. Decisions about contacting patients need a defined clinical and regulatory basis, not speculation generated during a stock search.1, 2, 4

Incident reporting remains separate

Healthcare professionals should continue to report suspected or actual adverse incidents involving the listed devices. In England and Wales the DSI directs reporting through the Yellow Card scheme or app. Scottish incidents should go to the Incident Reporting and Investigation Centre and the local incident system. Northern Ireland professionals should use the Yellow Card website in line with organisational medical device procedures. These routes collect clinical and product information that a compliance notification alone may not contain.1, 2

A notification that stock is held answers a different question from an adverse incident report. The compliance email tells the MHRA where affected products entered the supply chain and supports traceability. An incident report describes what happened during use, the condition of the device, any patient or staff effect and the action taken. Where both circumstances apply, both routes may be needed. Services should not assume that procurement has reported the clinical event or that a clinician’s Yellow Card report has completed the stock notification.1, 2

Incident descriptions should remain factual. Staff can record the product identifiers, procedure, observed behaviour, harm or near miss and preserved evidence without attributing causation that has not been established. The missing conformity evidence may be relevant context, but coincidence does not prove that it caused an event. Conversely, the regulator’s statement that no signal has yet been identified should not discourage reporting. New reports are one way a signal could become visible, particularly when products have been distributed across unrelated organisations.1, 2

Local incident review should also consider whether the alert process worked. A near miss in which quarantined stock remained in a trolley may reveal a communication or segregation failure even if the device itself did not malfunction. Review can trace the route from national notice to medical device safety officer, procurement, store and clinical user. The aim is to close a control gap while preserving the MHRA’s distinction between regulatory non-compliance and an identified product defect.1, 2

What procurement and governance should learn

The immediate task is the six named lines, not a general purge of imported or unfamiliar products. Longer term assurance should test whether suppliers provide the correct declaration, certificate where required, manufacturer and responsible person details, intended purpose, labelling and instructions before an item enters a catalogue. Documents should be checked for scope, issuer and validity rather than filed because they carry a compliance heading. The MHRA has previously warned that documents called certificates of compliance or attestations may have no legal standing under device law.1, 4, 3, 5

Contract terms should support traceability and rapid communication. A distributor needs to know which customers received a device, and a provider needs enough purchase and batch information to find it. Supply resilience also matters because an organisation may be reluctant to quarantine a familiar item if no alternative has been planned. Frameworks can require prompt notification of regulatory changes and identify substitute products in advance for essential procedures. These controls make it easier to follow an alert without shifting the decision to staff at the point of care.1, 4, 3, 5

Medical device safety officers and clinical engineering teams can use the event to test the alert register. The record should show when the notice arrived, who assessed relevance, which services were searched, what was found, how staff were informed and when actions closed. A zero stock result still needs a defensible search. Organisations that act as both provider and distributor should record each role separately. Board or committee oversight is most useful where it identifies repeated weaknesses in procurement data or alert completion rather than counting forwarded messages.1, 4, 3, 5

The bounded conclusion should remain visible when the incident is discussed. Six device lines lacked the valid conformity marking or certification needed for legal UK supply, so the MHRA required immediate cessation, quarantine, compliant alternatives, notification and traceability. The agency had not identified a defect, performance problem, quality issue or safety signal. Both facts support the same action. Regulatory assurance was insufficient, while evidence of product harm had not been established. Accurate language allows services to protect patients without presenting an unresolved documentation and market compliance problem as a proven clinical failure.1, 4, 3, 5